Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre

被引:24
作者
Bonnema, SJ [1 ]
Nielsen, VE [1 ]
Hegedüs, L [1 ]
机构
[1] Odense Univ Hosp, Dept Endocrinol & Metab, DK-5000 Odense C, Denmark
关键词
D O I
10.1530/eje.0.1500439
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The long-term effects of I-131-therapy in patients with symptomatic non-toxic diffuse goitre were evaluated. Design and methods: In a prospective open study, 34 patients (median age: 40 yrs, range: 27-68 yrs) were enrolled who suffered from a non-toxic goitre absent of nodules on clinical examination and on ultrasonography. Treatment indication was the presence of goitre giving rise to cervical compression and/or cosmetic discomfort. The median I-131 activity was 600 MBq (200-600 MBq) administered orally on an outpatient basis. The patients were investigated by clinical examination, thyroid ultrasonography and thyroid function tests at regular intervals and for at least 12 months after the I-131-therapy. Yearly follow-up continued until the end of the study period or if permanent hypothyroidism ensued. The severity of symptoms was evaluated by a Visual Analogue Scale (VAS) (range: 0-10). Results: The median follow-up time was 36 months (12-84). Goitre volume was reduced from 67.9 +/- 28.5 ml to 43.4 +/- 18.7ml (mean +/- S.D.) (P < 0.001) 3 months after the I-131-therapy. After 3 years of follow-up, only 28.1+/-2.0% (mean +/- S.E.) remained of the initial goitre, mass (P < 0.001). Goitre was no longer present in 76% of the patients at the end of follow-up. An inverse correlation was found 1 year after therapy, but not after 3 years, between the initial goitre size and the percent reduction (r = -0.44, P = 0.01). Thirty-six percent had become hypothyroid after three years. Median VAS scores were reduced from an initial 7.0 (cervical compression) and 5.5 (cosmetic discomfort) to 0.0 at the end of follow-up (P < 0.001). Conclusion: Our data justify treatment of non-toxic diffuse goitre with I-131 because goitre reduction is pronounced, along with a very high degree of patient satisfaction and few side effects. We suggest that I-131-therapy can be used as an alternative to L-T-4 suppressive therapy and thyroidectomy in this group of patients.
引用
收藏
页码:439 / 445
页数:7
相关论文
共 28 条
[1]  
AlSuliman NN, 1997, EUR J SURG, V163, P13
[2]   COMPARISON OF PLACEBO WITH L-THYROXINE ALONE OR WITH CARBIMAZOLE FOR TREATMENT OF SPORADIC NONTOXIC GOITER [J].
BERGHOUT, A ;
WIERSINGA, WM ;
DREXHAGE, HA ;
SMITS, NJ ;
TOUBER, JL .
LANCET, 1990, 336 (8709) :193-197
[3]   INTERRELATIONSHIPS BETWEEN AGE, THYROID VOLUME, THYROID NODULARITY, AND THYROID-FUNCTION IN PATIENTS WITH SPORADIC NONTOXIC GOITER [J].
BERGHOUT, A ;
WIERSINGA, WM ;
SMITS, NJ ;
TOUBER, JL .
AMERICAN JOURNAL OF MEDICINE, 1990, 89 (05) :602-608
[4]   LT4-MONOPREPARATION VERSUS LT4-LT3-COMPOUND PREPARATION IN THE TREATMENT OF DIFFUSE ENDEMIC GOITER [J].
BONGERS, H ;
HOTZE, LA ;
SCHMITZ, R ;
JOSEPH, K .
ACTA ENDOCRINOLOGICA, 1986, 113 (02) :242-248
[5]   The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter:: Effect on thyroid function and size and pulmonary function [J].
Bonnema, SJ ;
Bertelsen, H ;
Mortensen, J ;
Andersen, PB ;
Knudsen, DU ;
Bastholt, L ;
Hegedüs, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) :3636-3641
[6]   Management of the nontoxic multinodular goitre:: A European questionnaire study [J].
Bonnema, SJ ;
Bennedbæk, FN ;
Wiersinga, WM ;
Hegedüs, L .
CLINICAL ENDOCRINOLOGY, 2000, 53 (01) :5-12
[7]   Management of the nontoxic multinodular goiter:: A north American survey [J].
Bonnema, SJ ;
Bennedbæk, FN ;
Ladenson, PW ;
Hegedüs, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :112-117
[8]  
deKlerk JMH, 1997, J NUCL MED, V38, P372
[9]   Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study [J].
Franklyn, JA ;
Maisonneuve, P ;
Sheppard, M ;
Betteridge, J ;
Boyle, P .
LANCET, 1999, 353 (9170) :2111-2115
[10]   CANCER MORTALITY AFTER I-131 THERAPY FOR HYPERTHYROIDISM [J].
HALL, P ;
BERG, G ;
BJELKENGREN, G ;
BOICE, JD ;
ERICSSON, UB ;
HALLQUIST, A ;
LIDBERG, M ;
LUNDELL, G ;
TENNVALL, J ;
WIKLUND, K ;
HOLM, LE ;
LINDBERG, S ;
CEDERQUIST, E ;
WICKLUND, H ;
LARSSON, LG .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (06) :886-890